Pharmacokinetics Services Market Size and Forecast (2021-2031)

According to our latest study on “Pharmacokinetics Services Market Forecast to 2031 – Global Analysis – Drug Type, Service Type, Therapeutic Application, and End User,” the market value is expected to reach US$ 1,579.87 million by 2031 from US$ 874.96 million in 2023; the market is estimated to record a CAGR of 7.6% during 2023–2031. The report highlights the key factors driving the pharmacokinetics services market growth and prominent players with their developments in the market.

The pharmacokinetics services market has been segmented on the basis of drug type, service type, therapeutic application, and end user. By drug type, the market is segmented into small molecules, large molecules, and vaccines. The small molecule segment held the largest market share in 2023. Pharmacokinetics service companies provide comprehensive PK/PD (i.e., pharmacokinetics and pharmacodynamics) services to evaluate the fundamental physicochemical properties and structural motifs that are responsible for the efficacy and safety profile of small molecules. These services include PK bioanalysis; PD biomarker analysis; high-throughput absorption, distribution, metabolism, and excretion (HT-ADME) profiling; in vitro ADME assays; drug transporter assays; and non-radiolabeled and radiolabeled in vivo ADME studies. In vitro ADME studies are crucial in gaining insights into metabolism and potential drug interactions. Companies also offer drug interaction screening services, including in vitro ADME assays, data interpretation systems, and expert study designs, to determine the ADME properties of small molecules.

By service type, the pharmacokinetics services market is segmented into preclinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The preclinical ADME and human studies segment held the largest market share in 2023. The segment is further anticipated to register the highest CAGR during the forecast period. Drug development is a costly process for pharmaceutical and biotechnology manufacturers, and a drug’s inability to meet safety profiles often leads to failure in the final stages of clinical studies. ADME toxicology testing is meant to address this issue in the early stages of drug development, i.e., during preclinical trials. Toxicology testing is a crucial step before introducing a new drug to the market to ensure its safety. This testing aids in the better understanding of drug levels and kinetics after its exposure to the human body, reducing the time and costs of drug discovery. Preclinical ADME toxicology testing is an important aspect of drug discovery for venture capital (VC) firms, as study outcomes help them make informed financial decisions. In January 2024, CN Bio and Altis Biosystems agreed to work together to develop a next-generation human gut/liver in vitro model for advanced ADME studies. Such inorganic growth strategies adopted by market players are contributing to the pharmacokinetics market growth for the preclinical ADME and human studies segment.

The pharmacokinetics services market, by therapeutic application, is categorized into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023. Further, the infectious diseases segment is anticipated to register the highest CAGR during the forecast period. Human immunodeficiency virus (HIV) is a major public health issue across the world. As per the World Health Organization (WHO), nearly 58 million individuals across the world have chronic hepatitis C virus infection, and ~1.5 million new infections occur every year. Critically ill patients who suffer from severe infections are at a high risk of receiving antimicrobial drugs in suboptimal doses. PK/PD modeling is a technique used to describe and measure the relationship between drug dose, concentration, and effect. Laboratories that specialize in the treatment of patients with serious infections, such as HIV, fungal infections, and tuberculosis, focus on providing therapeutic drug monitoring using liquid chromatography-mass spectrometry (LC-MS). Therapeutic drug monitoring (TDM) is a well-established clinical tool that allows clinicians to perform ADME and clearance studies. It also helps clinicians determine the necessary doses of drugs for each patient while taking into account the complex drug–drug interactions. The Infectious Disease Pharmacokinetics Laboratory at the University of Florida (IDPL) offers drug assays that most other clinical labs do not provide.

The pharmacokinetics services market, by end user, is categorized into pharmaceutical and biotechnology companies, contract research organizations, and others. The contract research organization segment held the largest market share in 2023. It is further anticipated to register the highest CAGR during the forecast period. Contract research organizations provide services to support the pharmaceutical, biotechnology, and medical device industries. These services usually include in vivo PD and Pharmacokinetics services, PK/PD modeling, DMPK analysis, and PK mouse and rat models. PK/PD studies play a crucial role in the drug discovery process. They generate high-quality data on the pharmacokinetic (PK) and pharmacodynamic (PD) properties of drug candidates.

Charles River Laboratories International Inc., Eurofins Scientific SE, Evotec SE, Certara Inc., Parexel International Corp, Thermo Fisher Scientific Inc., Allucent, PACIFIC BIOLABS, SGS SA, and Shanghai Medicilon Inc. are among the leading companies operating in the global Pharmacokinetics Services market.

Companies operating in the Pharmacokinetics Services market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the Pharmacokinetics Services market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall Pharmacokinetics Services market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

A few of the significant developments by key market players are listed below.

• Thermo Fisher Scientific expanded its clinical research operations with the opening of a state-of-the-art bioanalytical lab in Richmond, Virginia. The new unit will support the burgeoning demand generated in the biopharmaceutical ecosystem for consistent, high-quality laboratory services to accelerate drug development. The Richmond Bioanalytical Lab, whose entities have been operating since 1985, provides services for all phases of small molecule drug, biologics, vaccine, and biomarker development. Drug testing services include drug PK/PD, and immunogenicity and biomarker quantitation to support drug efficacy and safety. (Source: Thermo Fisher Scientific, Press Release, October 2022)

• Charles River Laboratories International, Inc., partnered with Kibur Medical to offer exclusive access to its implantable microdevice (IMD) for in vivo preclinical oncology studies. Kibur’s microdevice technology can hold up to 20 different compounds for local administration, which allows it to dose therapies directly into disease tissue, allowing for investigative studies of early-stage compounds where pharmacokinetic properties are poorly understood. (Source: Charles River Laboratories International, Inc., Newsletter, February 2021).

1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Pharmacokinetics Services Market Landscape
4.1 PEST Analysis
5. Pharmacokinetics Services Market – Key Market Dynamics
5.1 Pharmacokinetics Services Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Prevalence of Chronic and Infectious Diseases
5.2.2 Expanding Range of Application of Pharmacokinetic Studies
5.2.3 Outsourcing of Pharmacokinetics Services to CROs
5.3 Market Restraints
5.3.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
5.4 Market Opportunities
5.4.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
5.5 Future Trend
5.5.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
5.6 Impact of Drivers and Restraints:
6. Pharmacokinetics Services Market – Global Market Analysis
6.1 Pharmacokinetics Services Market Revenue (US$ Million), 2023–2031
7. Pharmacokinetics Services Market Analysis – by Drug Type
7.1 Overview
7.2 Small Molecule
7.2.1 Overview
7.2.2 Small Molecule: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Large Molecule
7.3.1 Overview
7.3.2 Large Molecule: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Vaccines
7.4.1 Overview
7.4.2 Vaccines: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8. Pharmacokinetics Services Market Analysis – by Service Type
8.1 Pre-Clinical ADME and Human Studies
8.1.1 Overview
8.1.2 Pre-Clinical ADME and Human Studies: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.2 PK/PD Analysis and Reporting
8.2.1 Overview
8.2.2 PK/PD Analysis and Reporting: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Dosing Simulations
8.3.1 Overview
8.3.2 Dosing Simulations: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Risk Analysis
8.4.1 Overview
8.4.2 Risk Analysis: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9. Pharmacokinetics Services Market Analysis – by Therapeutic Application
9.1 Oncology
9.1.1 Overview
9.1.2 Oncology: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.2 Infectious Diseases
9.2.1 Overview
9.2.2 Infectious Diseases: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.3 Neurological Disorders
9.3.1 Overview
9.3.2 Neurological Disorders: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.4 Autoimmune Diseases
9.4.1 Overview
9.4.2 Autoimmune Diseases: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.5 Gynecological Disorders
9.5.1 Overview
9.5.2 Gynecological Disorders: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.6 Cardiovascular Diseases
9.6.1 Overview
9.6.2 Cardiovascular Diseases: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.7 Respiratory Disorders
9.7.1 Overview
9.7.2 Respiratory Disorders: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.8 Others
9.8.1 Overview
9.8.2 Others: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10. Pharmacokinetics Services Market Analysis – by End User
10.1 Pharmaceutical and Biotechnology Companies
10.1.1 Overview
10.1.2 Pharmaceutical and Biotechnology Companies: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.2 Contract Research Organization
10.2.1 Overview
10.2.2 Contract Research Organization: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.3 Others
10.3.1 Overview
10.3.2 Others: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11. Pharmacokinetics Services Market – Geographical Analysis
11.1 North America
11.1.1 North America Pharmacokinetics Services Market Overview
11.1.2 North America: Pharmacokinetics Services Market – Revenue and Forecast Analysis – by Country
11.1.2.1 United States: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.1.2.1.1 Overview
11.1.2.1.2 United States: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.1.2.1.3 United States: Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.2.1.4 United States: Pharmacokinetics Services Market Breakdown, by Service Type
11.1.2.1.5 United States: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.2.1.6 United States: Pharmacokinetics Services Market Breakdown, by End User
11.1.2.2 Canada: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.1.2.2.1 Overview
11.1.2.2.2 Canada: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.1.2.2.3 Canada: Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.2.2.4 Canada: Pharmacokinetics Services Market Breakdown, by Service Type
11.1.2.2.5 Canada: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.2.2.6 Canada: Pharmacokinetics Services Market Breakdown, by End User
11.1.2.3 Mexico: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.1.2.3.1 Overview
11.1.2.3.2 Mexico: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.1.2.3.3 Mexico: Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.2.3.4 Mexico: Pharmacokinetics Services Market Breakdown, by Service Type
11.1.2.3.5 Mexico: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.2.3.6 Mexico: Pharmacokinetics Services Market Breakdown, by End User
11.2 Europe
11.2.1 Europe Pharmacokinetics Services Market Overview
11.2.2 Europe: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.3 Pharmacokinetics Services Market Breakdown by Countries
11.2.4 Pharmacokinetics Services Market Revenue and Forecast and Analysis – by Country
11.2.4.1 Germany: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.1.1 Overview
11.2.4.1.2 Germany: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.1.3 Germany: Pharmacokinetics Services Market Breakdown, by Drug Type
11.2.4.1.4 Germany: Pharmacokinetics Services Market Breakdown, by Service Type
11.2.4.1.5 Germany: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.2.4.1.6 Germany: Pharmacokinetics Services Market Breakdown, by End User
11.2.4.2 France: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.2.1 Overview
11.2.4.2.2 France: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.2.3 France: Pharmacokinetics Services Market Breakdown, by Drug Type
11.2.4.2.4 France: Pharmacokinetics Services Market Breakdown, by Service Type
11.2.4.2.5 France: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
The market for infectious diseases segment is estimated to be worth US$ 19.24 million by 2031 and is expected to register a CAGR of 10.8% during the 2023–2031.
11.2.4.2.6 France: Pharmacokinetics Services Market Breakdown, by End User
11.2.4.3 United Kingdom: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.3.1 Overview
11.2.4.3.2 United Kingdom: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.3.3 United Kingdom: Pharmacokinetics Services Market Breakdown, by Drug Type
11.2.4.3.4 United Kingdom: Pharmacokinetics Services Market Breakdown, by Service Type
11.2.4.3.5 United Kingdom: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.2.4.3.6 United Kingdom: Pharmacokinetics Services Market Breakdown, by End User
11.2.4.4 Italy: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.4.1 Overview
11.2.4.4.2 Italy: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.4.3 Italy: Pharmacokinetics Services Market Breakdown, by Drug Type
11.2.4.4.4 Italy: Pharmacokinetics Services Market Breakdown, by Service Type
11.2.4.4.5 Italy: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.2.4.4.6 Italy: Pharmacokinetics Services Market Breakdown, by End User
11.2.4.5 Spain: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.5.1 Overview
11.2.4.5.2 Spain: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.5.3 Spain: Pharmacokinetics Services Market Breakdown, by Drug Type
11.2.4.5.4 Spain: Pharmacokinetics Services Market Breakdown, by Service Type
11.2.4.5.5 Spain: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.2.4.5.6 Spain: Pharmacokinetics Services Market Breakdown, by End User
11.2.4.6 Rest of Europe: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.6.1 Overview
11.2.4.6.2 Rest of Europe: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.6.3 Rest of Europe: Pharmacokinetics Services Market Breakdown, by Drug Type
11.2.4.6.4 Rest of Europe: Pharmacokinetics Services Market Breakdown, by Service Type
11.2.4.6.5 Rest of Europe: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.2.4.6.6 Rest of Europe: Pharmacokinetics Services Market Breakdown, by End User
11.3 Asia Pacific
11.3.1 Asia Pacific Pharmacokinetics Services Market Overview
11.3.2 Asia Pacific: Pharmacokinetics Services Market
11.3.3 Asia Pacific: Pharmacokinetics Services Market – Revenue and Forecast Analysis – by Country
11.3.3.1 China: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.1.1 Overview
11.3.3.1.2 China: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.1.3 China: Pharmacokinetics Services Market Breakdown, by Drug Type
11.3.3.1.4 China: Pharmacokinetics Services Market Breakdown, by Service Type
11.3.3.1.5 China: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.3.3.1.6 China: Pharmacokinetics Services Market Breakdown, by End User
11.3.3.2 Japan: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.2.1 Overview
11.3.3.2.2 Japan: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.2.3 Japan: Pharmacokinetics Services Market Breakdown, by Drug Type
11.3.3.2.4 Japan: Pharmacokinetics Services Market Breakdown, by Service Type
11.3.3.2.5 Japan: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.3.3.2.6 Japan: Pharmacokinetics Services Market Breakdown, by End User
11.3.3.3 India: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.3.1 Overview
11.3.3.3.2 India: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.3.3 India: Pharmacokinetics Services Market Breakdown, by Drug Type
11.3.3.3.4 India: Pharmacokinetics Services Market Breakdown, by Service Type
11.3.3.3.5 India: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.3.3.3.6 India: Pharmacokinetics Services Market Breakdown, by End User
11.3.3.4 Australia: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.4.1 Overview
11.3.3.4.2 Australia: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.4.3 Australia: Pharmacokinetics Services Market Breakdown, by Drug Type
11.3.3.4.4 Australia: Pharmacokinetics Services Market Breakdown, by Service Type
11.3.3.4.5 Australia: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.3.3.4.6 Australia: Pharmacokinetics Services Market Breakdown, by End User
11.3.3.5 South Korea: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.5.1 Overview
11.3.3.5.2 South Korea: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.5.3 South Korea: Pharmacokinetics Services Market Breakdown, by Drug Type
11.3.3.5.4 South Korea: Pharmacokinetics Services Market Breakdown, by Service Type
11.3.3.5.5 South Korea: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.3.3.5.6 South Korea: Pharmacokinetics Services Market Breakdown, by End User
11.3.3.6 Rest of APAC: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.6.1 Overview
11.3.3.6.2 Rest of APAC: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.6.3 Rest of APAC: Pharmacokinetics Services Market Breakdown, by Drug Type
11.3.3.6.4 Rest of APAC: Pharmacokinetics Services Market Breakdown, by Service Type
11.3.3.6.5 Rest of APAC: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.3.3.6.6 Rest of APAC: Pharmacokinetics Services Market Breakdown, by End User
11.4 Middle East and Africa
11.4.1 Middle East and Africa Pharmacokinetics Services Market Overview
11.4.2 Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3 Pharmacokinetics Services Market Breakdown by Countries
11.4.4 Pharmacokinetics Services Market Revenue and Forecast and Analysis – by Country
11.4.5 Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast Analysis – by Country
11.4.5.1 Saudi Arabia: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.4.5.1.1 Overview
11.4.5.1.2 Saudi Arabia: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.4.5.1.3 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by Drug Type
11.4.5.1.4 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by Service Type
11.4.5.1.5 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.4.5.1.6 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by End User
11.4.5.2 South Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.4.5.2.1 Overview
11.4.5.2.2 South Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.4.5.2.3 South Africa: Pharmacokinetics Services Market Breakdown, by Drug Type
11.4.5.2.4 South Africa: Pharmacokinetics Services Market Breakdown, by Service Type
11.4.5.2.5 South Africa: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.4.5.2.6 South Africa: Pharmacokinetics Services Market Breakdown, by End User
11.4.5.3 United Arab Emirates: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.4.5.3.1 Overview
11.4.5.3.2 United Arab Emirates: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.4.5.3.3 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by Drug Type
11.4.5.3.4 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by Service Type
11.4.5.3.5 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.4.5.3.6 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by End User
11.4.5.4 Rest of Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.4.5.4.1 Overview
11.4.5.4.2 Rest of Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.4.5.4.3 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Drug Type
11.4.5.4.4 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Service Type
11.4.5.4.5 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.4.5.4.6 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by End User
11.5 South and Central America
11.5.1 South and Central America Pharmacokinetics Services Market Overview
11.5.2 South and Central America: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.5.3 Pharmacokinetics Services Market Breakdown by Countries
11.5.4 Pharmacokinetics Services Market Revenue and Forecast and Analysis – by Country
11.5.4.1 Brazil: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.5.4.1.1 Overview
11.5.4.1.2 Brazil: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.5.4.1.3 Brazil: Pharmacokinetics Services Market Breakdown, by Drug Type
11.5.4.1.4 Brazil: Pharmacokinetics Services Market Breakdown, by Service Type
11.5.4.1.5 Brazil: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.5.4.1.6 Brazil: Pharmacokinetics Services Market Breakdown, by End User
11.5.4.2 Argentina: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.5.4.2.1 Overview
11.5.4.2.2 Argentina: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.5.4.2.3 Argentina: Pharmacokinetics Services Market Breakdown, by Drug Type
11.5.4.2.4 Argentina: Pharmacokinetics Services Market Breakdown, by Service Type
11.5.4.2.5 Argentina: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.5.4.2.6 Argentina: Pharmacokinetics Services Market Breakdown, by End User
11.5.4.3 Rest of South and Central America: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.5.4.3.1 Overview
11.5.4.3.2 Rest of South and Central America: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.5.4.3.3 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by Drug Type
11.5.4.3.4 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by Service Type
11.5.4.3.5 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.5.4.3.6 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by End User
12. Company Profile
12.1 Charles River Laboratories International Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Eurofins Scientific SE
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Evotec SE
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Certara Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.5 Parexel International Corp
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Thermo Fisher Scientific Inc.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Allucent
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 PACIFIC BIOLABS
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 SGS SA
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Shanghai Medicilon Inc.
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About the Research Team

Table 1. Pharmacokinetics Services Market Segmentation
Table 2. United States: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 3. United States: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 4. United States: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 5. United States: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 6. Canada: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 7. Canada: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 8. Canada: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 9. Canada: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 10. Mexico: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 11. Mexico: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 12. Mexico: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 13. Mexico: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 14. Germany: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 15. Germany: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 16. Germany: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 17. Germany: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 18. France: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 19. France: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 20. France: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 21. France: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 22. United Kingdom: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 23. United Kingdom: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 24. United Kingdom: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 25. United Kingdom: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 26. Italy: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 27. Italy: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 28. Italy: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 29. Italy: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 30. Spain: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 31. Spain: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 32. Spain: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 33. Spain: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 34. Rest of Europe: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 35. Rest of Europe: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 36. Rest of Europe: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 37. Rest of Europe: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 38. China: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 39. China: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 40. China: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 41. China: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 42. Japan: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 43. Japan: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 44. Japan: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 45. Japan: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 46. R&D Expenditure of Indian Companies, 2018–2020 (US$ Million)
Table 47. Company
Table 48. India: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 49. India: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 50. India: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 51. India: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 52. Australia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 53. Australia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 54. Australia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 55. Australia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 56. South Korea: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 57. South Korea: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 58. South Korea: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 59. South Korea: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 60. Rest of APAC: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 61. Rest of APAC: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 62. Rest of APAC: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 63. Rest of APAC: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 64. Saudi Arabia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 65. Saudi Arabia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 66. Saudi Arabia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 67. Saudi Arabia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 68. South Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 69. South Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 70. South Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 71. South Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 72. United Arab Emirates: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 73. United Arab Emirates: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 74. United Arab Emirates: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 75. United Arab Emirates: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 76. Rest of Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 77. Rest of Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 78. Rest of Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 79. Rest of Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 80. Brazil: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 81. Brazil: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 82. Brazil: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 83. Brazil: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 84. Argentina: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 85. Argentina: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 86. Argentina: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 87. Argentina: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 88. Rest of South and Central America: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 89. Rest of South and Central America: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 90. Rest of South and Central America: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 91. Rest of South and Central America: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User

Figure 1. Pharmacokinetics Services Market Segmentation, by Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Pharmacokinetics Services Market Revenue (US$ Million), 2023–2031
Figure 5. Pharmacokinetics Services Market, By Geography Forecast Analysis, 2023 & 2031
Figure 6. Pharmacokinetics Services Market Share (%) – by Drug Type (2023 and 2031)
Figure 7. Small Molecule: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. Large Molecule: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 9. Vaccines: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 10. Pharmacokinetics Services Market Share (%) – by Service Type (2023 and 2031)
Figure 11. Pre-Clinical ADME and Human Studies: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 12. PK/PD Analysis and Reporting: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Dosing Simulations: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 14. Risk Analysis: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 15. Others: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 16. Pharmacokinetics Services Market Share (%) – by Therapeutic Application (2023 and 2031)
Figure 17. Oncology: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 18. Infectious Diseases: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 19. Neurological Disorders: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 20. Autoimmune Diseases: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 21. Gynecological Disorders: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 22. Cardiovascular Diseases: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 23. Respiratory Disorders: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 24. Others: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 25. Pharmacokinetics Services Market Share (%) – by End User (2023 and 2031)
Figure 26. Pharmaceutical and Biotechnology Companies: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 27. Contract Research Organization: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 28. Others: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 29. North America: Pharmacokinetics Services Market by Key Countries – Revenue (2023) US$ Million
Figure 30. North America: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 31. North America: Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 32. United States: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 33. Canada: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 34. Mexico: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 35. Europe: Pharmacokinetics Services Market – Revenue by Key Countries Revenue 2023 (US$ Million)
Figure 36. Europe: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 37. Europe: Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 38. Germany: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 39. France: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 40. United Kingdom: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 41. Italy: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 42. Spain: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 43. Rest of Europe: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 44. Asia Pacific: Pharmacokinetics Services Market – Revenue by Key Countries 2023 (US$ Million)
Figure 45. Asia Pacific: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 46. Asia Pacific: Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 47. China: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 48. Japan: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 49. India: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 50. Australia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 51. South Korea: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 52. Rest of APAC: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 53. Middle East and Africa: Pharmacokinetics Services Market by Key Countries – Revenue 2023 (US$ Million)
Figure 54. Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 55. Pharmacokinetics Services Market Breakdown by Key Countries, 2023 and 2031 (%)
Figure 56. Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 57. Saudi Arabia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 58. South Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 59. United Arab Emirates: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 60. Rest of Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 61. South and Central America: Pharmacokinetics Services Market by Key Countries – Revenue 2023 (US$ Million)
Figure 62. South and Central America: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 63. Pharmacokinetics Services Market Breakdown by Key Countries, 2023 and 2031 (%)
Figure 64. Brazil: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 65. Argentina: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 66. Rest of South and Central America: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)